Evaluation of 2 Doses of Intravenous Droperidol in the Prevention of Postoperative Nausea (DIPAVO)
Primary Purpose
Nausea, Vomiting
Status
Terminated
Phase
Phase 4
Locations
France
Study Type
Interventional
Intervention
Droperidol
Sponsored by
About this trial
This is an interventional prevention trial for Nausea focused on measuring Thyroidectomy, Nausea, Vomiting, Droperidol
Eligibility Criteria
Inclusion Criteria:
- Female
- More than 18 years old
- Patients scheduled for thyroid surgery
- Simplified Apfel score ≥ 2
- ASA score : 1-2
- Informed consent obtained from the patient
- Women able to procreate must have a reliable contraceptive method
Exclusion Criteria:
- Age < 18 years old
- Male
- Obesity
- Has a severe depressive syndrome
- Pregnancy women
- Trouble with cardiac rate
- Alcoholism
- Contra-indication for Droperidol prescription
Sites / Locations
- Département d'Anesthésie-Réanimation II ; Groupe Hospitalier Sud, CHU de Bordeaux
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
1
2
3
Arm Description
Intravenous injection of 0,625 mg Droperidol, 30 min before the end of anesthesia
Intravenous injection of 2,5 mg Droperidol, 30 min before the end of anesthesia
Intravenous injection of NaCl 9% (Placebo), 30 min before the end of anesthesia
Outcomes
Primary Outcome Measures
No vomiting episode
Secondary Outcome Measures
Light nausea
Control of nausea
Anti-vomiting treatment
Adverse events
Modification of electrocardiograph
- Score of sedation
Full Information
NCT ID
NCT00445055
First Posted
March 6, 2007
Last Updated
December 12, 2011
Sponsor
University Hospital, Bordeaux
Collaborators
Prostrakan Pharmaceuticals
1. Study Identification
Unique Protocol Identification Number
NCT00445055
Brief Title
Evaluation of 2 Doses of Intravenous Droperidol in the Prevention of Postoperative Nausea
Acronym
DIPAVO
Official Title
Study of Evaluation of the Profile of Efficiency / Tolerance of 2 Doses of Intravenous Droperidol in the Prevention of the Postoperative Nausea and Vomits Related to the Surgery of the Thyroid
Study Type
Interventional
2. Study Status
Record Verification Date
December 2011
Overall Recruitment Status
Terminated
Study Start Date
April 2007 (undefined)
Primary Completion Date
April 2009 (Actual)
Study Completion Date
April 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Bordeaux
Collaborators
Prostrakan Pharmaceuticals
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
In this prospective, randomised, placebo-controlled study, the researchers determined whether 0.625 mg or 2.5 mg of IV droperidol given 30 min before emergence from general anaesthesia reduces the incidence of immediate and delayed post operative nausea and vomiting (PONV) in thyroid surgical female population. Two hundred and forty six female patients receiving general anaesthesia for thyroid surgery received either droperidol 0.625 mg or droperidol 2.5 mg or placebo before emergence.
Detailed Description
Principal Objective : Our study examined one main question: Are there difference in efficacy between droperidol IV 0.625 mg or 2.5 mg for the treatment or prophylaxis of PONV to surgical patient undergoing thyroid surgery when they receive it 30 min before emergence from general anaesthesia?
Secondary Objective :
comparison of the % of patients in every group:
having a complete control of their nausea
requiring secondarily the appeal to another anti-emetic treatment in postoperative
presenting an Adverse event
Compare score of sedation in ach groups
Evaluate electrocardiograph
Compare the morphine consumption
Study design : Prospective, randomized, monocenter, double-blind study
Inclusion criteria :
Female
More than 18 years old
Patients scheduled for thyroid surgery
Simplified Apfel score ≥ 2
ASA score : 1-2
Informed consent obtained from the patient
the women in age of procreate must have a reliable contraceptive method
Exclusion criteria :
age < 18 years old
male
obesity
present a severe depressive syndrome
pregnancy women
trouble of cardiac rate
alcoholism
contra-indication for Droperidol prescription
Study plan: three parallel groups will receive 2 different doses of Droperidol or placebo at the end of surgery.
Group 1: 0,625mg of Droperidol at the end of surgery
Group 2: 2,5mg of Droperidol at the end of surgery
Group 3: Placebo at the end of surgery
Number of subjects : 246
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nausea, Vomiting
Keywords
Thyroidectomy, Nausea, Vomiting, Droperidol
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
71 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Intravenous injection of 0,625 mg Droperidol, 30 min before the end of anesthesia
Arm Title
2
Arm Type
Experimental
Arm Description
Intravenous injection of 2,5 mg Droperidol, 30 min before the end of anesthesia
Arm Title
3
Arm Type
Placebo Comparator
Arm Description
Intravenous injection of NaCl 9% (Placebo), 30 min before the end of anesthesia
Intervention Type
Drug
Intervention Name(s)
Droperidol
Intervention Description
Intravenous injection
Primary Outcome Measure Information:
Title
No vomiting episode
Time Frame
During the first four hours after intervention
Secondary Outcome Measure Information:
Title
Light nausea
Time Frame
24h post operative
Title
Control of nausea
Time Frame
24h post operative
Title
Anti-vomiting treatment
Time Frame
24h post operative
Title
Adverse events
Time Frame
24h post operative
Title
Modification of electrocardiograph
Time Frame
30 min and 120 min after injection
Title
- Score of sedation
Time Frame
24h post operative
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Female
More than 18 years old
Patients scheduled for thyroid surgery
Simplified Apfel score ≥ 2
ASA score : 1-2
Informed consent obtained from the patient
Women able to procreate must have a reliable contraceptive method
Exclusion Criteria:
Age < 18 years old
Male
Obesity
Has a severe depressive syndrome
Pregnancy women
Trouble with cardiac rate
Alcoholism
Contra-indication for Droperidol prescription
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gérard JANVIER, MD
Organizational Affiliation
University Hospital, Bordeaux
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Laure BAUDOUIN, Dr
Organizational Affiliation
University Hospital, Bordeaux
Official's Role
Principal Investigator
Facility Information:
Facility Name
Département d'Anesthésie-Réanimation II ; Groupe Hospitalier Sud, CHU de Bordeaux
City
PESSAC Cedex
ZIP/Postal Code
33604
Country
France
12. IPD Sharing Statement
Citations:
PubMed Identifier
10730546
Citation
Kovac AL. Prevention and treatment of postoperative nausea and vomiting. Drugs. 2000 Feb;59(2):213-43. doi: 10.2165/00003495-200059020-00005.
Results Reference
background
PubMed Identifier
8031342
Citation
Williams OA, Clarke FL, Harris RW, Smith P, Peacock JE. Addition of droperidol to patient-controlled analgesia: effect on nausea and vomiting. Anaesthesia. 1993 Oct;48(10):881-4. doi: 10.1111/j.1365-2044.1993.tb07419.x.
Results Reference
background
PubMed Identifier
12818945
Citation
Gan TJ, Meyer T, Apfel CC, Chung F, Davis PJ, Eubanks S, Kovac A, Philip BK, Sessler DI, Temo J, Tramer MR, Watcha M; Department of Anesthesiology, Duke University Medical Center. Consensus guidelines for managing postoperative nausea and vomiting. Anesth Analg. 2003 Jul;97(1):62-71, table of contents. doi: 10.1213/01.ane.0000068580.00245.95.
Results Reference
background
PubMed Identifier
10389804
Citation
Wang JJ, Ho ST, Lee SC, Liu YC, Liu YH, Liao YC. The prophylactic effect of dexamethasone on postoperative nausea and vomiting in women undergoing thyroidectomy: a comparison of droperidol with saline. Anesth Analg. 1999 Jul;89(1):200-3. doi: 10.1097/00000539-199907000-00036.
Results Reference
background
PubMed Identifier
10875717
Citation
Henzi I, Sonderegger J, Tramer MR. Efficacy, dose-response, and adverse effects of droperidol for prevention of postoperative nausea and vomiting. Can J Anaesth. 2000 Jun;47(6):537-51. doi: 10.1007/BF03018945.
Results Reference
background
Learn more about this trial
Evaluation of 2 Doses of Intravenous Droperidol in the Prevention of Postoperative Nausea
We'll reach out to this number within 24 hrs